[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lacunar-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lacunar-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,74,103,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100601520","phase-4-lacunar-stroke-hyperacute-clinical-utilization-of-novel-approach-regimens-rt-pa-vs-dapt-randomised-clinical-trial-100601520",false,"NCT07111559","Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial","A Multicenter Randomized Controlled Trial Comparing Tissue Plasminogen Activator With Dual Antiplatelet Therapy for Patients With Hyperacute Single Perforating Artery Infarction","LACUNAR-tPA","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Acute ischemic stroke within 4.5 hours from onset. If onset time is unknown because of impaired consciousness or aphasia, use the \"last known well\" time.\n* A single perforating-artery infarct on brain MRI:\n\nlocated in the corona radiata, putamen, internal capsule, thalamus, or pons; solitary, mainly round or oval, with a maximum diameter ≤ 20 mm; lesions only in the centrum semiovale are not allowed, but extension from the above sites into the centrum semiovale is allowed.\n\n* No disability in daily life before the stroke (modified Rankin Scale ≤ 1).\n* National Institutes of Health Stroke Scale (NIHSS) score ≤ 5.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Antithrombotic therapy considered inappropriate because of active bleeding, low platelet count, or similar conditions.\n* Any contraindication to intravenous rt-PA, without blood pressures.\n* ≥ 50 % stenosis or occlusion of the artery responsible for the stroke \\* (see note below).\n* Diseases that require anticoagulation (e.g., atrial fibrillation, deep-vein thrombosis) \\*\n* Inability to take medicine orally.\n* Any other reason judged by the principal investigator or co-investigators to make participation inappropriate.\n\nNote: This study targets hyper-acute stroke within 4.5 hours. To avoid treatment delay, items marked with \\* must be judged using the similar examinations that each site normally performs before rt-PA administration.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke). The main questions it aims to answer are:\n\nIs a combination of antiplatelet drugs non-inferior to the current standard tissue plasminogen activator treatment? Does a combination of antiplatelet drugs reduce the bleeding complications than tissue plasminogen activator?\n\nResearchers will compare a combination of antiplatelet drugs to tissue plasminogen activator to see if a combination of antiplatelet drugs works to treat small ischemic stroke (lacunar stroke).\n\nParticipants will:\n\nTake a combination of antiplatelet drugs or be given intravenous tissue plasminogen activator Check the neurological status 3 months after stroke, in-person, by phone, or by mail.",[27,28,29],"Lacunar Stroke","Stroke","Ischemic Stroke",[31,32,33,34,35,36],"rt-PA","tissue-plasminogen activator","DAPT","dual antiplatelet therapy","minor stroke","lacunar stroke","RECRUITING","2026-06-04",{"date":40,"type":41},"2026-06-05","ACTUAL",{"date":43,"type":41},"2025-08-01",{"date":45,"type":21},"2029-03-31",{"name":47,"class":48},"Nippon Medical School","OTHER",28,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100548083","retinal-vessel-leakage-in-cerebral-small-vessel-disease-100548083","NCT06416371","Retinal Vessel Leakage in Cerebral Small Vessel Disease","Retinal Vessel Leakage in Cerebral Small Vessel Disease: a Sub-study of the Mild Stroke Study 3","Inclusion Criteria:\n\n* Membership in the Mild Stroke Study 3 cohort\n* Contrast enhanced MRI within 12 months\n* Clear optical media in both eyes, as assessed by study investigator\n* Best corrected visual acuity (near vision) ≥N36\n\nExclusion Criteria:\n\n* Any condition known to cause retinal leakage (i.e., worse than background diabetic retinopathy, retinal vein occlusion, active uveitis, wet age-related macular degeneration, malignant hypertension)\n* Previous treatment for retinal leakage (retinal laser, intravitreal anti-VEGF)\n* Recent eye surgery\n* Shallow anterior chambers as assessed by torch test\n* Pregnancy, renal failure\n* Severe dementia\n* Known allergy to fluorescein\n* History of allergy such as food or drug induced urticaria or history of bronchial asthma\n* Any other severe or acute medical or psychiatric conditions\n* Inability to give informed consent",{"count":58,"type":21},40,"OBSERVATIONAL","The goal of this observational study is to learn about leakage from retinal vessels in cerebral small vessel disease. The main questions it aims to answer are:\n\n* Does retinal vessel leakage occur in cerebral small vessel disease?\n* If it does, is the severity of retinal vessel leakage similar to the severity of cerebral small vessel disease generally?\n\nParticipants will be tested using fluorescein angiography. This involves an intravenous injection of fluorescent dye, and is a very sensitive way to find leakage from retinal blood vessels.\n\nParticipants will have already had brain scans and other examinations and tests to measure the severity of their cerebral small vessel disease. Our new retinal images will complement the information from these previous tests.",[62,27,63],"Cerebral Small Vessel Diseases","Vascular Dementia","2026-03-02",{"date":66,"type":41},"2026-03-04",{"date":68,"type":41},"2025-01-13",{"date":70,"type":21},"2029-02-15",{"name":72,"class":48},"University of Edinburgh",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":73},"100620115","a-multicenter-randomized-clinical-trial-compared-with-standard-clinical-practice-to-evaluate-the-efficacy-of-a-polyphenol-rich-salicornia-extract-in-the-progression-of-cognitive-decline-in-a-cohort-of-patients-with-lacunar-infarcts-salacunar-100620115","NCT07353424","A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polyphenol-rich Salicornia Extract in the Progression of Cognitive Decline in a Cohort of Patients With Lacunar Infarcts (SALACUNAR)","A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polyphenol-rich Salicornia Extract in the Progression of Cognitive Decline in a Cohort of Patients With Lacunar Infarcts","SALACUNAR","Inclusion Criteria:\n\n\\- Patients with lacunar ischemic stroke, confirmed by cranial magnetic resonance imaging performed within the year prior to inclusion, who have an mRS of 3 or less at the time of inclusion will be included (independent patients or those who require assistance with walking). The inclusion age will be between 40 and 90 years.\n\nExclusion Criteria:\n\n* Consumption of vitamin supplements or polyphenol supplements within 30 days prior to inclusion\n* Hyperthyroidism\n* mRS \\>3, serious illness, or expected life expectancy \\\u003C12 months\n* Dysphagia preventing intake of the study capsules\n* Allergies or intolerance to halophytes\n* Pregnant or breastfeeding\n* Active neoplasia\n* Participation in another study","40 Years","90 Years",{"count":85,"type":21},300,[87],"NA","SALACUNAR (LACI-2-polyphenols) is a multi-center randomized controlled trial (RCT) to evaluate the effect of a polyphenol-rich supplement on small vessel neurovascular disease. Specifically, the compound to be tested is a dietary supplement based on Salicornia extract and B vitamins (B-salicornia), which in previous studies has demonstrated a good safety profile and consistent effects in reducing homocysteine levels and improving cognitive outcomes (MOCA) in patients with lacunar infarcts. This has been used to calculate the sample size based on these endpoints. Considering an intragroup variability of the treatment groups (sigma) of 6.07, and accepting an alpha risk of 0.05, a sample of 150 patients per group would achieve a 1-beta statistical power greater than 0.8 in a two-tailed test for differences between means of at least two points on the MOCA scale.\n\nThree hundred patients with lacunar infarcts diagnosed within the last year and confirmed by MRI performed as part of routine clinical practice will be included.\n\nWe will administer 500 mg\u002F24 h of the dietary supplement B-Salicornia for six months (or the control group will be managed according to routine clinical practice) following a PROBE design.\n\nRoutine blood tests will be performed pre- and post-treatment, with routine vascular parameters such as lipids and homocysteine, as well as baseline and six-month assessments of neuropsychological and gait scales.",[27],[91,92,93],"attack","food supplement","cognition","2026-01-19",{"date":96,"type":41},"2026-01-20",{"date":98,"type":41},"2025-06-01",{"date":100,"type":21},"2026-12-31",{"name":102,"class":48},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":73},"100556506","telecoached-exercise-intervention-for-connectivity-enhancement-in-small-vessel-disease-teleconnect-svd-100556506","NCT06525987","Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD)","Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD): a Randomized Clinical Trial","TELECONNECT","Inclusion Criteria:\n\n* Age ≥60 years;\n* History of lacunar stroke occurred between 3 months and 10 years from screening and confirmed by neuroimaging or clinical data by an expert stroke physician;\n* Modified Rankin Scale (mRS) score of 0-1, indicating no symptoms or no significant disability;\n* A level of physical activity below recommended targets, i.e. \\\u003C150 minutes per week of moderate-to-vigorous exercise (24);\n* Ability to sign informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension;\n* Heart disease impairing the possibility of safely following an exercise protocol at the discretion of the treating physician;\n* Primary or secondary epilepsy;\n* Prostheses, implants, and any device that might impair the performance of either high-density electroencephalogram or the exercise intervention;\n* Cognitive impairment (Mini Mental State Examination score ≤26 at follow-up);\n* Lack of access to Internet-based facilities or poor technological alphabetization impairing the adherence to the trial protocol;\n* Any major physical or psychiatric comorbidity that in the judgement of the treating physician might compromise the ability to undergo an exercise intervention.","60 Years",{"count":113,"type":21},60,[87],"The TELECONNECT-SVD study is a prospective, randomized, multicenter trial aimed at testing the efficacy of a remotely delivered exercise protocol on brain functional connectivity in patients with small vessel disease (SVD)-related ischemic stroke. The study will recruit patients aged ≥60 with a history of lacunar stroke, minimal disability (modified Rankin Scale score 0-1), and low physical activity levels.\n\nThe trial will include 60 participants randomized 1:1 to either a 24-week telecoached exercise intervention or usual care. The exercise program consists of multicomponent physical exercises delivered remotely twice a week. Assessments will be conducted at baseline, 12 weeks, 24 weeks, and 48 weeks.\n\nPrimary outcomes include changes in brain functional connectivity assessed by high-density EEG and improvements in physical fitness measured by the Senior Fitness Test. Secondary outcomes encompass changes in physical activity levels, anthropometric measurements, and vital signs.\n\nThe study employs a \"wait list\" design, where the control group receives the intervention after the initial 24-week period. This approach allows for assessment of the intervention's immediate effects and the retention of benefits after cessation.\n\nKey features of the protocol include:\n\n* Use of telecoaching to enhance adherence to the exercise program\n* Comprehensive assessment of brain connectivity using advanced EEG analysis techniques\n* Focus on patients with SVD, who may benefit significantly from exercise interventions\n* Evaluation of both neurophysiological and clinical outcomes\n\nThe study aims to provide evidence for the potential benefits of exercise in enhancing brain connectivity and physical fitness in SVD patients, potentially informing future treatment guidelines and preventive strategies for this population.",[27,117],"Small Vessel Cerebrovascular Disease","2025-11-24",{"date":120,"type":41},"2025-12-02",{"date":122,"type":41},"2025-05-02",{"date":100,"type":21},{"name":125,"class":48},"University of L'Aquila",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":73},"100543362","the-relationship-between-controlling-risk-factors-and-cerebral-haemodynamics-in-lacunar-stroke-100543362","NCT06354881","The Relationship Between Controlling Risk Factors and Cerebral Haemodynamics in Lacunar Stroke","Understanding the Relationship Between Controlling Risk Factors and Cerebral Haemodynamic Changes in Lacunar Stroke, and Its Interaction With Ageing","LACUNAR_CA","Inclusion Criteria:\n\n* Adults aged between 18-120 years.\n* Diagnosis of lacunar stroke syndrome.\n* New diagnosis or known diagnosis of hypertension and\u002For diabetes.\n\nExclusion Criteria:\n\n* Those who lack capacity can have a personal consultee consent to the study if they can still perform study requirements such as the sit-stand manoeuvre. Those who either cannot perform the manoeuvre or do not have a personal consultee to allow them to consent, are not able to take part.\n* Those with poorly controlled medical comorbidities affecting cerebral haemodynamics. (eg., heart failure).",{"count":135,"type":21},75,"The goal of this observational study is to look at differences in brain blood flow before and after management of risk factors such as high blood pressure and diabetes in patients with lacunar stroke. Participants will be asked to undergo a simple brain blood flow assessment at their initial appointment, whereby they will be asked to sit and stand twice. The patients will then be asked for a follow-up assessment 4 weeks after, identical to the first. This will allow us to look at any changes in brain blood flow from before management of risk factors and 4 weeks after management of risk factors.",[27],[139,28,140,141],"Lacunar","Cerebral Autoregulation","Cerebral Blood Flow","2025-03-21",{"date":144,"type":41},"2025-03-24",{"date":146,"type":41},"2024-05-02",{"date":148,"type":21},"2026-03",{"name":150,"class":48},"University of Leicester"]